These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38459924)

  • 1. Longitudinal Magnetic Resonance Imaging with ROS-Responsive Bilirubin Nanoparticles Enables Monitoring of Nonalcoholic Steatohepatitis Progression to Cirrhosis.
    Jung W; Asaduddin M; Keum H; Son Y; Yoo D; Kim D; Lee S; Lee DY; Roh J; Park SH; Jon S
    Adv Mater; 2024 Jun; 36(24):e2305830. PubMed ID: 38459924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive ROS imaging and drug delivery monitoring in the tumor microenvironment.
    Jung W; Asaduddin M; Yoo D; Lee DY; Son Y; Kim D; Keum H; Lee J; Park SH; Jon S
    Biomaterials; 2024 Oct; 310():122633. PubMed ID: 38810387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactive Oxygen Species-Responsive Delivery of a Notch Inhibitor to Alleviate Nonalcoholic Steatohepatitis by Inhibiting Hepatic
    Chen J; Zhang J; Xia Y; Li J; Jia Q; Zhang Z; Jing X; Xu Y; Zou L; Wang L; Song H; Li J; Liu Q; Xiong Y; Tang Q; Chen W; Yang N; Xu H; Li Y; He J
    Mol Pharm; 2024 Jun; 21(6):2922-2936. PubMed ID: 38751169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Nonalcoholic Fatty Liver Disease in Rats Using Quantitative Dynamic Contrast-Enhanced MRI.
    Wu Z; Cheng ZL; Yi ZL; Xie MW; Zeng H; Lu LJ; Xu X; Shen J
    J Magn Reson Imaging; 2017 May; 45(5):1485-1493. PubMed ID: 27606822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Combination of MR Elastography and Proton Density Fat Fraction Improves Diagnosis of Nonalcoholic Steatohepatitis.
    Alsaqal S; Hockings P; Ahlström H; Gummesson A; Hedström A; Hulthe J; Johansson L; Niessen HG; Schoelch C; Schultheis C; Vessby J; Wanders A; Rorsman F; Ebeling Barbier C
    J Magn Reson Imaging; 2022 Aug; 56(2):368-379. PubMed ID: 34953171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis.
    Andersson A; Kelly M; Imajo K; Nakajima A; Fallowfield JA; Hirschfield G; Pavlides M; Sanyal AJ; Noureddin M; Banerjee R; Dennis A; Harrison S
    Clin Gastroenterol Hepatol; 2022 Nov; 20(11):2451-2461.e3. PubMed ID: 34626833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials.
    Caussy C; Reeder SB; Sirlin CB; Loomba R
    Hepatology; 2018 Aug; 68(2):763-772. PubMed ID: 29356032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gd-EOB-DTPA-enhanced-MR imaging in the inflammation stage of nonalcoholic steatohepatitis (NASH) in mice.
    Yamada T; Obata A; Kashiwagi Y; Rokugawa T; Matsushima S; Hamada T; Watabe H; Abe K
    Magn Reson Imaging; 2016 Jul; 34(6):724-729. PubMed ID: 26979540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloperoxidase-Sensitive
    Liu J; Yu X; Ting HJ; Wang X; Xu S; Wang Y; Zhang S; Wang JW; Liu B
    ACS Nano; 2023 Feb; 17(4):3324-3333. PubMed ID: 36773320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of hepatic function using dynamic contrast-enhanced magnetic resonance imaging in melanocortin 4 receptor-deficient mice as a model of nonalcoholic steatohepatitis.
    Yamada T; Kashiwagi Y; Rokugawa T; Kato H; Konishi H; Hamada T; Nagai R; Masago Y; Itoh M; Suganami T; Ogawa Y; Abe K
    Magn Reson Imaging; 2019 Apr; 57():210-217. PubMed ID: 30465867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
    Younossi ZM; Loomba R; Anstee QM; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Goodman ZD; Chalasani NP; Kowdley KV; George J; Lindor K
    Hepatology; 2018 Jul; 68(1):349-360. PubMed ID: 29222917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative, noninvasive MRI characterization of disease progression in a mouse model of non-alcoholic steatohepatitis.
    Waghorn PA; Ferreira DS; Erstad DJ; Rotile NJ; Masia R; Jones CM; Tu C; Sojoodi M; Chen YI; Schlerman F; Wellen J; Martinez RVP; Tanabe KK; Fuchs BC; Caravan P
    Sci Rep; 2021 Mar; 11(1):6105. PubMed ID: 33731798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging biomarkers of NAFLD, NASH, and fibrosis.
    Ajmera V; Loomba R
    Mol Metab; 2021 Aug; 50():101167. PubMed ID: 33460786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a PEGylated Fibroblast Growth Factor 21 Variant Using Novel Preclinical Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Mouse Model of Nonalcoholic Steatohepatitis.
    Tang H; Li J; Zinker B; Boehm S; Mauer A; Rex-Rabe S; Glaser KJ; Fronheiser M; Bradstreet T; Nakao Y; Petrone T; Pena A; Villano M; Chow P; Malhi H; Charles ED; Hayes W; Ehman RL; Du S; Yin M
    J Magn Reson Imaging; 2022 Sep; 56(3):712-724. PubMed ID: 35092323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic Alanine Differentiates Nonalcoholic Steatohepatitis From Simple Steatosis in Humans and Mice: A Proton MR Spectroscopy Study With Long Echo Time.
    Kim TH; Jun HY; Kim KJ; Lee YH; Lee MS; Choi KH; Yun KJ; Jeong YY; Jun CH; Cho EY; Yoon KH
    J Magn Reson Imaging; 2017 Nov; 46(5):1298-1310. PubMed ID: 28225569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visco-Elastic Parameters at Three-Dimensional MR Elastography for Diagnosing Non-Alcoholic Steatohepatitis and Substantial Fibrosis in Mice.
    Khalfallah M; Doblas S; Hammoutene A; Julea F; Postic C; Valla D; Paradis V; Garteiser P; Van Beers BE
    J Magn Reson Imaging; 2024 Jan; 59(1):97-107. PubMed ID: 37158252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
    Castera L; Friedrich-Rust M; Loomba R
    Gastroenterology; 2019 Apr; 156(5):1264-1281.e4. PubMed ID: 30660725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Wu J
    Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic resonance imaging for the assessment of pathological hepatic findings in nonalcoholic fatty liver disease.
    Imajo K; Honda Y; Yoneda M; Saito S; Nakajima A
    J Med Ultrason (2001); 2020 Oct; 47(4):535-548. PubMed ID: 33108553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis.
    Noureddin M; Truong E; Gornbein JA; Saouaf R; Guindi M; Todo T; Noureddin N; Yang JD; Harrison SA; Alkhouri N
    J Hepatol; 2022 Apr; 76(4):781-787. PubMed ID: 34798176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.